From: To: Subject: Date: Attachments: Boris Nikolic "Jeffrey Epstein ([email protected])" <[email protected]> FW: Foundation Medicine Sun, 07 Jul 2013 20:15:49 +0000 Foundation Medicine_Cap_Table 6-30-13_- Summary.xls; FM_Fifth_Amended and RestateTI_Charter Lries EL(Filed).pdf; FM Series_B Stocc_Putaase_Agreement:Executa.pdf; FM- Third_AkR_Stockholders Voting_Agreement Series B Executed.pdf; FMI Second Closingn AmenTIment to_SPA_(2).ide FM13econd_Closing_- _IRA Adoption_Agreements.pdf; FM9 Second_Closing_- ROFI Adoption_Agreements.pdf; EXECUTED_ FM Gates_Side Letter.pdf; eharter:Amendment.pdf; FM_A&R Right_of_Fist_lcefusal_and_eo- Sale Agreement_Series B Executettpdf; FMTA&R_Investor_Riatc_Agreement_Series_B_Executed.pdf Check EXECUTED FM Gates sides letter — under 10 — Bill is THE ONLY investor and the owner of BGV B From: Rodi Guidero [mailto Sent: Sunday, July 7, 2013 8:13 AM To: Boris Nikolic Cc: John O'Brien; Mike Rodden; Alan Heuberger Subject: RE: Foundation Medicine Hi Boris, Here are the documents and current cap table. We don't have a distribution analysis, but that wouldn't apply in the context of a public offering since the preferred would convert to common. If there was a sale of the company instead, the preferred stockholders do have a liquidation preference that is equal to the amount they have invested - after that the remaining proceeds would go to common. This means that the liquidation preference would only come into play in a low value sale context. Above a certain value, the preferred holders would get more if they converted to common. We still understand that the company is pursuing a public offering. Have you heard something else? Thanks,Rodi From: Boris Nikolic fmailto: Sent: Saturday, July 06, 2013 10:43 AM To: Rodi Guider() Cc: John O'Brien; Mike Rodden; Alan Heuberger Subject: RE: Foundation Medidne EFTA01143225